Shell Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Shell Asset Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8,134	Closed	-$143K	–	1429
2021 Q3	$143K	Sell	8,134 -344	-4%	-$4.02K	﹤0.01%	1259
2021 Q2	$82K	Hold	8,478	–	–	﹤0.01%	1393
2021 Q1	$91K	Hold	8,478	–	–	﹤0.01%	1304
2020 Q4	$125K	Buy	+8,478	New	+$122K	﹤0.01%	1239

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Shell Asset Management's TRIL Position: Q4 2021 in Review

Shell Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 8,134 shares — an estimated $143K sold.

Shell Asset Management first reported a position in TRIL in Q4 2020 and held it in 4 quarters. The position peaked at $143K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Shell Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Shell Asset Management sold 8,134 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $143K.
Shell Asset Management first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 4 quarters.
Shell Asset Management's Trillium Therapeutics Inc. position peaked at $143K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Shell Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.